Executive Director Elizabeth Estes, Melissa Leichter of Novo Nordisk, and Panna Sharma of Lantern Pharma Inc. discussed the potential of using AI and machine learning to treat rare diseases.
During Alpha-1 Awareness Month, OSIC founding member CSL Behring shares three inspiring stories from the Alpha-1 Antitrypsin Deficiency community, one of which is a profile of OSIC’s research initiatives in this space.
Executive Director Elizabeth Estes discussed OSIC’s progress in developing biomarkers for rare lung disease as a result of collaboration between academia, industry and philanthropy.
Executive Director Elizabeth Estes shared insights on how robust clinical data curation, global normalization, and advanced data power can drive radical progress in drug development for fibrosing lung diseases.
Dr. Kevin Brown and Dr. Simon Walsh discussed recent developments in machine learning algorithms using the OSIC Cloud Data Repository during this Industry Theater presentation.
Executive Director Elizabeth Estes and Pam Factor-Litvak, PhD, associate dean for research resources at Columbia University Mailman School of Public Health, discussed “Open-Source as a Model to Advance Public Health Research.”
OSIC shared its expertise as part of a session that discussed “Leveling the Playing Field: How Imaging, AI and an Infinite Mindset Can Transform the Care of Patients with Rare Disease.”
OSIC discussed “Using Large, Longitudinal Databases to Predict Status of Disease Processes,” along with panelists from Columbia University; National Lung and Heart Institute/Imperial College London; and Massachusetts General Hospital/Harvard Medical School.
OSIC joined experts from PwC, Nuvance, and Memorial Sloan Kettering Cancer for a panel discussion about how healthcare systems are using a cloud-first approach to modernize their digital and data platforms, increase productivity, and create efficiencies.
